346 related articles for article (PubMed ID: 9120996)
21. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
22. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.
Lee BH; Heo SH; Kim GH; Park JY; Kim WS; Kang DH; Choe KH; Kim WH; Yang SH; Yoo HW
J Hum Genet; 2010 Aug; 55(8):512-7. PubMed ID: 20505683
[TBL] [Abstract][Full Text] [Related]
23. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
Fan JQ; Ishii S; Asano N; Suzuki Y
Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
[TBL] [Abstract][Full Text] [Related]
24. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
25. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online.
Chen CH; Shyu PW; Wu SJ; Sheu SS; Desnick RJ; Hsiao KJ
Hum Mutat; 1998; 11(4):328-30. PubMed ID: 9554750
[TBL] [Abstract][Full Text] [Related]
28. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
29. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
30. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.
Schäfer E; Baron K; Widmer U; Deegan P; Neumann HP; Sunder-Plassmann G; Johansson JO; Whybra C; Ries M; Pastores GM; Mehta A; Beck M; Gal A
Hum Mutat; 2005 Apr; 25(4):412. PubMed ID: 15776423
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female.
Rodríguez-Marí A; Coll MJ; Chabás A
Hum Mutat; 2003 Sep; 22(3):258. PubMed ID: 12938095
[TBL] [Abstract][Full Text] [Related]
32. Five novel mutations in fourteen patients with Fabry Disease.
Rosenberg KM; Schiffmann R; Kaneski C; Brady RO; Sorensen SA; Hasholt L
Hum Mutat; 2000 Feb; 15(2):207-8. PubMed ID: 10649504
[TBL] [Abstract][Full Text] [Related]
33. Fabry disease: 20 novel GLA mutations in 35 families.
Blaydon D; Hill J; Winchester B
Hum Mutat; 2001 Nov; 18(5):459. PubMed ID: 11668641
[TBL] [Abstract][Full Text] [Related]
34. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
35. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
36. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
37. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
Yam GH; Roth J; Zuber C
Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro expression study of four Fabry disease causing mutations at glutamine 279 of the alpha-galactosidase A protein.
Dominissini S; Cariati R; Nevyjel M; Guerci V; Ciana G; Bembi B; Pittis MG
Hum Hered; 2004; 57(3):138-41. PubMed ID: 15297807
[TBL] [Abstract][Full Text] [Related]
39. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease.
Rosenthal D; Lien YH; Lager D; Lai LW; Shang S; Leung N; Fervenza FC
Am J Kidney Dis; 2004 Nov; 44(5):e85-9. PubMed ID: 15492942
[TBL] [Abstract][Full Text] [Related]
40. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
